JP2022524994A5 - - Google Patents

Info

Publication number
JP2022524994A5
JP2022524994A5 JP2021552605A JP2021552605A JP2022524994A5 JP 2022524994 A5 JP2022524994 A5 JP 2022524994A5 JP 2021552605 A JP2021552605 A JP 2021552605A JP 2021552605 A JP2021552605 A JP 2021552605A JP 2022524994 A5 JP2022524994 A5 JP 2022524994A5
Authority
JP
Japan
Prior art keywords
amino acid
tcr
acid sequence
constant region
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021552605A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022524994A (ja
JP7576037B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/051813 external-priority patent/WO2020178744A1/en
Publication of JP2022524994A publication Critical patent/JP2022524994A/ja
Publication of JP2022524994A5 publication Critical patent/JP2022524994A5/ja
Application granted granted Critical
Publication of JP7576037B2 publication Critical patent/JP7576037B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021552605A 2019-03-04 2020-03-03 T細胞受容体及びその使用方法 Active JP7576037B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962813651P 2019-03-04 2019-03-04
US62/813,651 2019-03-04
PCT/IB2020/051813 WO2020178744A1 (en) 2019-03-04 2020-03-03 T cell receptors and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2022524994A JP2022524994A (ja) 2022-05-11
JP2022524994A5 true JP2022524994A5 (cg-RX-API-DMAC7.html) 2023-03-13
JP7576037B2 JP7576037B2 (ja) 2024-10-30

Family

ID=72337383

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021552605A Active JP7576037B2 (ja) 2019-03-04 2020-03-03 T細胞受容体及びその使用方法

Country Status (13)

Country Link
US (1) US12611450B2 (cg-RX-API-DMAC7.html)
EP (1) EP3935172A4 (cg-RX-API-DMAC7.html)
JP (1) JP7576037B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210144737A (cg-RX-API-DMAC7.html)
CN (1) CN113785065B (cg-RX-API-DMAC7.html)
AU (1) AU2020231694A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021017479A2 (cg-RX-API-DMAC7.html)
CA (1) CA3132438A1 (cg-RX-API-DMAC7.html)
IL (1) IL286044A (cg-RX-API-DMAC7.html)
MX (1) MX2021010537A (cg-RX-API-DMAC7.html)
SG (1) SG11202109595TA (cg-RX-API-DMAC7.html)
TW (1) TWI877143B (cg-RX-API-DMAC7.html)
WO (1) WO2020178744A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021010537A (es) 2019-03-04 2021-12-10 Univ Health Network Receptores de linfocitos t y metodos de uso de estos.
AU2020231927A1 (en) 2019-03-04 2021-09-30 University Health Network T cell receptors and methods of use thereof
US12522644B2 (en) 2019-03-04 2026-01-13 University Health Network T cell receptors and methods of use thereof
AU2020231693A1 (en) 2019-03-04 2021-09-30 University Health Network T cell receptors and methods of use thereof
CA3133945A1 (en) 2019-03-25 2020-10-01 University Health Network T cell receptors and methods of use thereof
CN122459332A (zh) * 2023-10-20 2026-07-24 百欧恩泰欧洲股份公司 多特异性t细胞衔接体组合物及其使用方法
CN117624340B (zh) * 2024-01-23 2024-04-30 北京臻知医学科技有限责任公司 识别人乙型肝炎病毒(hbv)抗原的t细胞受体(tcr)及其用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2323632A1 (en) 1998-03-13 1999-09-16 Epimmune Inc. Hla-binding peptides and their uses
CA2388301C (en) 1999-10-22 2011-01-04 Aventis Pasteur Limited Modified gp100 and uses thereof
US6506875B1 (en) 2000-09-26 2003-01-14 Ludwig Institute For Cancer Research Isolated peptides which bind to HLA-C molecules and uses thereof
WO2006031221A1 (en) * 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
WO2008007329A2 (en) 2006-07-11 2008-01-17 Nxp B.V. Calibration of transmit signals in fdd-transceivers
CA2674445C (en) * 2007-01-12 2016-06-07 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Gp100-specific t cell receptors and related materials and methods of use
CA2682093A1 (en) 2007-03-29 2008-10-09 Technion Research & Development Foundation Ltd. Antibodies, methods and kits for diagnosing and treating melanoma
EP3031916B1 (en) 2007-06-11 2017-06-07 Takara Bio Inc. Method for expression of specific gene
GB0720118D0 (en) * 2007-10-15 2007-11-28 Achour Adnane Modified mhc class 1 binding peptides
WO2010037395A2 (en) 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
WO2010112962A1 (en) * 2009-04-02 2010-10-07 Vaxon Biotech Identification, optimization and use of cryptic hla-a24 epitopes for immunotherapy
US9314516B2 (en) 2010-05-04 2016-04-19 Cassian Yee Conditional superagonist CTL ligands for the promotion of tumor-specific CTL responses
ES2635335T3 (es) 2010-09-20 2017-10-03 Biontech Cell & Gene Therapies Gmbh Receptores de células T específicos de antígeno y epítopos de células T
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CN105555756B (zh) 2013-06-28 2018-12-07 奥克兰联合服务有限公司 氨基酸缀合物和肽缀合物及缀合方法
KR101503341B1 (ko) 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
CA2964785A1 (en) 2014-11-05 2016-05-12 Board Of Regents, The University Of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
JP6895975B2 (ja) 2016-01-06 2021-06-30 ヘルス リサーチ インコーポレイテッドHealth Research, Inc. 組換えt細胞受容体を含む組成物及びライブラリー並びに組換えt細胞受容体を使用する方法
JP2019521080A (ja) 2016-04-27 2019-07-25 ユニバーシティ・ヘルス・ネットワーク ペプチド−hla複合体およびその産生方法
MX2021010537A (es) 2019-03-04 2021-12-10 Univ Health Network Receptores de linfocitos t y metodos de uso de estos.
BR112021017404A2 (pt) 2019-03-04 2022-02-01 Univ Health Network Receptores de células t e métodos de uso dos mesmos
CA3132434A1 (en) 2019-03-04 2020-09-10 University Health Network T cell receptors and methods of use thereof
AU2020231693A1 (en) 2019-03-04 2021-09-30 University Health Network T cell receptors and methods of use thereof
EP3935173A4 (en) 2019-03-04 2023-05-31 University Health Network T-CELL RECEPTORS AND METHODS OF USE THEREOF
US12522644B2 (en) 2019-03-04 2026-01-13 University Health Network T cell receptors and methods of use thereof
AU2020231927A1 (en) 2019-03-04 2021-09-30 University Health Network T cell receptors and methods of use thereof
CA3133945A1 (en) 2019-03-25 2020-10-01 University Health Network T cell receptors and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2022527267A5 (cg-RX-API-DMAC7.html)
JP2022524993A5 (cg-RX-API-DMAC7.html)
JP2022523552A5 (cg-RX-API-DMAC7.html)
JP2022523554A5 (cg-RX-API-DMAC7.html)
JP2022523971A5 (cg-RX-API-DMAC7.html)
JP2022523553A5 (cg-RX-API-DMAC7.html)
JP2022524992A5 (cg-RX-API-DMAC7.html)
Baxevanis et al. Cancer immunotherapy
JP2022543059A5 (cg-RX-API-DMAC7.html)
Shilyansky et al. T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines.
EP2446897A1 (en) Anti-KIR combination treatments and methods
Tsang et al. Phenotypic stability of a cytotoxic T-cell line directed against an immunodominant epitope of human carcinoembryonic antigen.
US20170232070A1 (en) Combination Methods for Immunotherapy
Junghans The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective
US11951131B2 (en) Anti-SLAMF7 chimeric antigen receptors
CN108138148A (zh) T细胞的激活和扩增
CN107847585A (zh) 用于得到体内存留性和治疗活性的nkt细胞亚群以及其繁殖
JP2022543060A5 (cg-RX-API-DMAC7.html)
JP2022543058A5 (cg-RX-API-DMAC7.html)
CA3052803A1 (en) Maximizing t-cell memory and compositions and methods therefor
AU2020231694A1 (en) T cell receptors and methods of use thereof
JP2020533962A5 (cg-RX-API-DMAC7.html)
JP2023548974A (ja) T細胞抗原カプラを含む細胞及びその使用
JP2023542528A5 (cg-RX-API-DMAC7.html)
JP2023521219A5 (cg-RX-API-DMAC7.html)